Xylonix Secures Exclusive Distribution Rights for Invitrocue’s Onco-PDO and ADPS Cancer Diagnostics in Korea and Japan

“The partnership will deliver Real-Time Cancer Adaptive Treatment Program accessible to Korean and Japanese patients."

Singapore, July 29, 2025 -Xylonix Pte. Ltd., a Singapore-based leader in oncology-focused healthcare solutions, is proud to announce a strategic partnership with Invitrocue Pte. Ltd., a pioneer in advanced cancer diagnostics. Xylonix has secured exclusive marketing and distribution rights for Invitrocue’s Onco-PDO and ADPS (Genecast) in vitro diagnostic products in South Korea and Japan, and a marketing & distribution partner in Singapore. This collaboration delivers cutting-edge precision oncology solutions to cancer patients, healthcare providers, and investors across Northeast Asia.

Transforming Cancer Care with Precision Diagnostics

Invitrocue’s Onco-PDO and ADPS technologies combine to enable a groundbreaking Real-Time Cancer Adaptive Treatment program, empowering doctors and patients with real-time insights allowing them to dynamically adjust cancer treatments for maximum therapeutic outcomes throughout the treatment course. Onco-PDO, approved in five countries including Germany, where it is nationally insured, delivers up to 94% accurate patient-derived organoid testing to guide tailored treatment plans for advanced-stage cancer patients. ADPS, the ADPS-PCR liquid biopsy solution by Genecast, Korea, for which Invitrocue is the global exclusive distributor, provides ultrasensitive in-blood cancer DNA detection at up to 0.001% mutant allele frequency—100x more sensitive than conventional next-generation sequencing (NGS) standards—for real-time mutation monitoring. These technologies enable oncologists to optimize treatment efficacy with data-driven precision.

Xylonix will deploy its robust marketing and distribution expertise to deliver these diagnostics to leading cancer centers and hospitals in South Korea, Japan, and Singapore, integrating them with its oncology-focused OTC and supplement products to enhance patient care.

Strategic Impact for Patients and Doctors

Xylonix expands access to Invitrocue’s diagnostics through a hub-and-spoke model, with major cancer centers serving as hubs and regional hospitals submitting samples for testing. In South Korea and Japan, Xylonix’s exclusive rights drive rapid market adoption, while in expanding Invitrocue’s reach in Singapore. This model ensures diagnostics are accessible across urban and regional areas, combining Invitrocue’s technologies with Xylonix’s supportive care products to address both immediate and long-term patient needs.

Dr. Jinhuyuk Chung, CEO of Xylonix, stated, “Our partnership with Invitrocue brings their revolutionary Onco-PDO and ADPS technologies to Asia. Supported by our hub-and-spoke approach, we aim to improve patient outcomes and strengthen our role as a trusted partner to oncologists.”

Addressing a Multi-Billion Dollar Market

The partnership targets Asia’s precision oncology market, valued at approximately $50 billion by 2030, driven by 4.5 million new cancer cases annually across South Korea, Japan, and Singapore (based on regional cancer incidence data and a 10-12% CAGR). South Korea and Japan account for over $30 billion in potential revenue, with Singapore adding $5 billion, fueled by demand for effective personalized medicine.

Hub-and-Spoke Model: Expanding Reach and Revenue Potential

Based on cutting-edge AI analyses, the hub-and-spoke model maximizes patient access and revenue for each hub cancer center. Most hubs, located in major cancer centers across South Korea, Japan, and Singapore, serve populations exceeding 20 million, with leading hubs projected to care for over 10,000 patients annually. Hubs centralize advanced diagnostic testing using Invitrocue’s Onco-PDO and ADPS technologies, while regional hospitals feed samples for processing. For example, hubs in Greater Seoul (25.7M population) and Kanto/Tohoku (51.8M population) are expected to serve thousands of patients. Across seven hubs in South Korea and Japan, Xylonix aims to capture the demands of 14,000–62,150 patients in the initial years, capturing a significant share of the $50 billion market and offering strong revenue for each hub.

Commitment to Excellence and Compliance

Both companies are committed to maintaining the highest standards of intellectual property protection and confidentiality, ensuring the integrity of this partnership while adhering to local regulations in South Korea, Japan, and Singapore.

About Xylonix Pte. Ltd.

Xylonix Pte. Ltd., headquartered in Singapore, specializes in immunity and oncology-focused healthcare solutions, offering innovative OTC and supplement products designed to support cancer patients’ immediate needs, as well as first-in-class immunotherapy innovations for aggressive cancers and autoimmune disorders. With a commitment to improving patient outcomes, Xylonix bridges cutting-edge diagnostics and accessible care, delivering comprehensive solutions to oncology markets across Asia.

About Invitrocue Pte. Ltd.

Invitrocue Pte. Ltd., a Singapore-based biotechnology company, is a leader in precision oncology, developing Onco-PDO and in-licensed ADPS technologies that redefine personalized cancer treatment. With clinical approvals in five countries, including national insurance coverage in Germany, Invitrocue is poised to transform cancer care through innovative diagnostic solutions.

Contact

For media inquiries or investor relations, please contact:

Xylonix Pte. Ltd.

Email: contact@xylonix.io

Invitrocue Pte. Ltd.

Email: martind.bach@invitrocue.com

Disclaimer: This press release is for informational purposes only. Investors should conduct their own due diligence.